Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Selexys chooses Cytovance for process development services
August 2007
SHARING OPTIONS:

OKLAHOMA CITYŚCytovance Biologics LLC, a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from mammalian cell culture, announced that Selexys Pharmaceuticals Corp. selected Cytovance for a range of process development services supporting acceleration of its anti-adhesion antibody programs. "The contract with Cytovance represents a major step forward for Selexys as we move our portfolio of engineered humanized antibodies toward clinical development," says Richard Alvarez, COO of Selexys. "We will initially advance our anti-P-selectin program for the treatment of sickle cell disease as a lead indication."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.